Last Updated: 10 Nov 2024
Executive Summary
Integra LifeSciences Holdings (IART) is a leading medical device company with a strong focus on surgical implants and instruments. The company has a solid financial position with a market capitalization of $19.12 billion and an EBITDA of $323.11 million. While the company's earnings per share (EPS) is currently negative at -$0.09, it is expected to improve in the future. Analysts have a mixed outlook on the stock, with 1 strong buy rating, 2 buy ratings, 6 hold ratings, 3 sell ratings, and 2 strong sell ratings. The current stock price is $24.78, which is below the analyst target price of $28.63.
Company Overview
Integra LifeSciences Holdings develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, limb reconstruction, orthopedics, and general surgery. The company's products are used in a variety of procedures, including spine surgery, orthopedic surgery, and wound care. Integra LifeSciences Holdings is headquartered in Princeton, New Jersey, and has operations in over 30 countries.
Fundamental Analysis
Integra LifeSciences Holdings has a strong financial position with a market capitalization of $19.12 billion and an EBITDA of $323.11 million. The company's revenue for the past twelve months was $1.56 billion, and its gross profit was $982.03 million. The company's net income was -$8.9 million, and its diluted EPS was -$0.09.
Integra LifeSciences Holdings has a number of strengths, including its strong brand recognition, its wide range of products, and its global reach. The company also has a number of weaknesses, including its high debt levels and its exposure to foreign currency fluctuations.
Technical Analysis
The technical analysis of Integra LifeSciences Holdings shows that the stock is currently in a downtrend. The stock price has been falling since early 2023, and it is currently below its 50-day and 200-day moving averages. The stock's relative strength index (RSI) is also below 50, which indicates that the stock is oversold.
Short Term Outlook
The short-term outlook for Integra LifeSciences Holdings is mixed. The stock is currently in a downtrend, and there are no signs of a reversal. The company's earnings are also expected to remain negative in the near term. As a result, investors should be cautious about investing in Integra LifeSciences Holdings in the short term.
Long Term Outlook
The long-term outlook for Integra LifeSciences Holdings is more positive. The company has a strong brand, a wide range of products, and a global reach. The company's debt levels are also manageable, and its exposure to foreign currency fluctuations is limited. As a result, investors should consider investing in Integra LifeSciences Holdings for the long term.
Analyst Recommendations
Analysts have a mixed outlook on Integra LifeSciences Holdings. The average analyst rating is "hold," and the average analyst target price is $28.63. One analyst has a strong buy rating, two analysts have buy ratings, six analysts have hold ratings, three analysts have sell ratings, and two analysts have strong sell ratings.
